Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: A post hoc analysis

Syed M. Mohiuddin, Kamlesh M. Thakker, Carolyn M. Setze, Maureen T. Kelly

Research output: Contribution to journalArticle

5 Scopus citations


Objective: To evaluate the achievement of individual and combined lipid and lipoprotein/biomarker targets as specified by treatment guidelines with the combination of fenofibric acid and statin therapy in patients with mixed dyslipidemia. Methods: Data for the post hoc analyses were derived from three 12-week controlled studies and a 52-week extension study. Patients were treated with fenofibric acid 135 mg; low-, moderate-, or high-dose statin (rosuvastatin 10, 20, or 40 mg; atorvastatin 20, 40, or 80 mg; or simvastatin 20, 40, or 80 mg); or fenofibric acid + low- or moderate-dose statin in the controlled studies; and with fenofibric acid + moderate-dose statin in the extension study. Achievement of risk-stratified low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (ApoB) targets; and optimal levels of ApoB 40/50 mg/dL in men/women, triglycerides (TG)

Original languageEnglish
Pages (from-to)1067-1078
Number of pages12
JournalCurrent Medical Research and Opinion
Issue number5
Publication statusPublished - May 2011


All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this